How to Get Retatrutide in 2026: Clinical Trials, Timeline & What to Know
Reviewed by Peptide Nerds Editorial · Updated March 2026
This article is for informational purposes only and does not constitute medical advice. We do not sell peptides or any pharmaceutical products. Always consult a licensed healthcare provider before starting any treatment. For our full disclaimer, visit our disclaimer page.
Key Takeaways
- Retatrutide is not FDA-approved as of March 2026. It cannot be legally prescribed or purchased.
- Clinical trial enrollment is currently the only legitimate way to access retatrutide.
- FDA approval is expected between mid-2026 and early 2027, with commercial availability likely in early to mid-2027.
- Projected cost will likely fall between $1,000 and $1,500 per month without insurance, based on comparable GLP-1 medications.
- Websites claiming to sell retatrutide are selling unverified research chemicals with no quality control. Avoid them.
- FDA-approved alternatives like semaglutide and tirzepatide are available now for weight loss.
Current Status: March 2026
Retatrutide is Eli Lilly's investigational triple-agonist peptide. It targets three receptors simultaneously: GLP-1, GIP, and glucagon. Phase 2 trials showed unprecedented weight loss results, with participants losing up to 24% of body weight over 48 weeks.
But here is the reality. Retatrutide is not FDA-approved. It is not available by prescription. It is not legally sold online by any pharmacy, clinic, or supplement company.
If you want to understand what makes this peptide different, we break it down in our full retatrutide guide. But if you are searching for how to actually get it right now, keep reading.
Get the Peptide Starter Kit (free)
A quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
The Only Legal Way: Clinical Trial Enrollment
As of early 2026, the only legitimate path to receiving retatrutide is through participation in a clinical trial.
Eli Lilly is running multiple Phase 3 trials. Two of the most relevant are:
- NCT05882045 (TRIUMPH-3): A large-scale obesity trial evaluating retatrutide for chronic weight management.
- NCT06383390: Evaluating retatrutide for weight loss in adults with type 2 diabetes.
You can search for all active retatrutide trials at ClinicalTrials.gov. Use the search term "retatrutide" and filter by your location to find trials near you.
How to Search for Trials
- Go to ClinicalTrials.gov.
- Enter "retatrutide" in the search bar.
- Filter by "Recruiting" status and your geographic location.
- Review the eligibility criteria for each trial.
- Contact the listed study coordinator to begin the screening process.
Many trial sites are located at academic medical centers and large research hospitals. Availability depends on your area. Not every trial is open at every location.
What the Clinical Trial Process Looks Like
Enrolling in a clinical trial is not the same as getting a prescription. Here is what to expect.
Screening and Eligibility
Most retatrutide obesity trials require participants to meet specific criteria. Typical requirements include:
- BMI of 30 or higher (clinical obesity), or
- BMI of 27 or higher with at least one weight-related comorbidity (such as high blood pressure, type 2 diabetes, or high cholesterol)
- No recent use of other GLP-1 medications
- No history of certain medical conditions (varies by trial)
You will go through a screening visit that includes bloodwork, physical examination, and a review of your medical history.
Randomization
Clinical trials use randomization to ensure scientific validity. This means you may be assigned to the retatrutide group or to a placebo group. In a placebo-controlled trial, there is no guarantee you will receive the active drug.
Some trials are "dose-finding" studies where all participants receive retatrutide, but at different doses. The trial protocol will specify this.
Monitoring Requirements
Participants are closely monitored throughout the trial. Expect regular clinic visits (often monthly), blood draws, body composition measurements, and adverse event reporting. Trial participation is a time commitment.
The benefit is that you receive medical supervision, regular health monitoring, and access to a cutting-edge treatment at no cost.
FDA Approval Timeline
Phase 3 trials for retatrutide are expected to produce results in early to mid-2026. After that, Eli Lilly will submit a New Drug Application (NDA) to the FDA.
Here is the realistic timeline:
| Milestone | Expected Timing |
|---|---|
| Phase 3 trial data readout | Early-mid 2026 |
| NDA submission to FDA | Mid 2026 |
| FDA review period | 6-12 months |
| Potential approval | Mid-2026 to early 2027 |
| Commercial availability | Early to mid-2027 |
The FDA can grant Priority Review (6 months) or follow the standard review timeline (10-12 months). Given the obesity epidemic and strong Phase 2 data, Priority Review is plausible but not guaranteed.
For a deeper analysis of the approval timeline, see our retatrutide FDA approval timeline article.
Expected Cost When Available
Eli Lilly has not announced pricing for retatrutide. But we can make educated projections based on comparable medications already on the market.
| Medication | Monthly Cost (List Price) |
|---|---|
| Wegovy (semaglutide) | ~$1,300/month |
| Zepbound (tirzepatide) | ~$1,060/month |
| Retatrutide (projected) | ~$1,000-$1,500/month |
Retatrutide is a triple-agonist, which Eli Lilly may position as a premium product. However, the company has shown willingness to price competitively. Zepbound launched below Wegovy's price point, and Lilly has offered manufacturer savings programs and copay cards.
Insurance coverage will be a major factor. Many insurers now cover GLP-1 medications for obesity, though coverage is not universal. Employer plans, Medicare, and Medicaid each have different rules. The landscape is shifting quickly in favor of coverage, particularly as evidence for cardiovascular and metabolic benefits grows.
For a full breakdown of what retatrutide treatment involves, see our dosage guide.
What About Compounding Pharmacies?
Compounding pharmacies have become a popular source for GLP-1 medications. Compounded semaglutide, for example, has been widely available at lower price points during FDA-declared drug shortages.
Retatrutide is in a different situation. It is not yet FDA-approved, which means it has no official patent-protected market. But more importantly, it has no FDA-approved reference product for compounders to work from.
Compounding pharmacies legally produce medications based on approved drugs. Without an FDA approval for retatrutide, legitimate compounding of it is not expected in the near term. This may change after approval and depending on supply conditions, but it is not a realistic option in 2026.
Warning: Avoid Online "Retatrutide" Sellers
This is the section we wish we did not have to write. But it is necessary.
Multiple websites currently claim to sell retatrutide online. These products are marketed as "research chemicals" or "peptides for research purposes only." Some even include dosing instructions, which contradicts their "not for human use" disclaimers.
These are unverified, unregulated substances. Here is what you are risking:
- No quality control. There is no third-party verification that the vial contains what the label claims.
- Contamination risk. Unregulated manufacturing facilities may introduce bacterial contamination, heavy metals, or other impurities.
- Incorrect dosing. Without pharmaceutical-grade manufacturing, the actual concentration may differ significantly from what is stated.
- No medical supervision. Using injectable peptides without physician oversight increases the risk of adverse events.
The FDA has issued warnings about purchasing unapproved peptides online. This is not a gray area. Injecting unverified substances is a real health risk.
For more on retatrutide's safety profile from clinical data, see our side effects page.
What to Do While You Wait
If you are interested in retatrutide for weight loss, the good news is that highly effective, FDA-approved options exist right now.
Semaglutide (brand names Wegovy and Ozempic) is a GLP-1 receptor agonist with extensive clinical data. Average weight loss in trials was approximately 15% of body weight.
Tirzepatide (brand names Zepbound and Mounjaro) is a dual GLP-1/GIP agonist. It showed even stronger weight loss results, with participants losing up to 22.5% of body weight in trials.
Both are available by prescription. Both have established safety profiles. Both can be discussed with your doctor today.
Retatrutide's triple-agonist mechanism may offer additional benefits. But the data is still being confirmed in Phase 3 trials. Waiting for a drug that is not yet available when proven treatments exist is a trade-off worth discussing with your healthcare provider.
Read our full comparison in our retatrutide for weight loss article.
Frequently Asked Questions
Can I buy retatrutide online?
No. Any website selling retatrutide is selling unregulated research chemicals. Retatrutide is not FDA-approved and cannot be legally sold as a medication. We strongly advise against purchasing injectable peptides from unverified sources.
When will retatrutide be available by prescription?
Based on the current clinical trial timeline, FDA approval could come as early as mid-2026. Commercial availability would likely follow in early to mid-2027.
How much will retatrutide cost?
Pricing has not been announced. Based on comparable GLP-1 medications, expect a list price between $1,000 and $1,500 per month without insurance. Eli Lilly typically offers savings programs that can reduce out-of-pocket costs.
Is retatrutide better than semaglutide or tirzepatide?
Phase 2 data suggests retatrutide may produce greater weight loss than both semaglutide and tirzepatide. However, Phase 3 data is still pending. Direct comparisons will require head-to-head trials, which have not been completed.
How do I enroll in a retatrutide clinical trial?
Visit ClinicalTrials.gov, search for "retatrutide," filter by recruiting studies in your area, and contact the study coordinator listed on the trial page.
Will my insurance cover retatrutide?
It is too early to say. Insurance coverage will depend on FDA approval, your specific plan, and whether your insurer covers anti-obesity medications. Coverage for GLP-1 drugs has been expanding, which is a positive signal.
Last updated: March 6, 2026
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.